LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Inicio・Lista de Acciones・Fate Therapeutics Inc

Fate Therapeutics Inc

Cerrado

SectorSalud

1.25 5.93

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.23

Máximo

1.25

Métricas clave
By Trading Economics
Ingresos	1.8M -32M
Ventas	-166K 1.7M
Margen de beneficio	-1,852.384
Empleados	181
EBITDA	7.9M -29M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+219.17% upside

Dividendos
By Dow Jones
Próximas Ganancias	3 mar 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	3.5M 129M
Apertura anterior	-4.68
Cierre anterior	1.25

Noticias sobre sentimiento de mercado

By Acuity

50%

155 / 352 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

0.9101 / 1.14 Soporte y Resistencia

Fate Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

13 feb 2026, 16:32 UTC

Ganancias

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

13 feb 2026, 21:57 UTC

Ganancias

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

13 feb 2026, 21:20 UTC

Ganancias

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13 feb 2026, 21:05 UTC

Adquisiciones, fusiones, absorciones

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13 feb 2026, 20:45 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

13 feb 2026, 20:45 UTC

Charlas de Mercado

Dollar Pares Down Early Losses -- Market Talk

13 feb 2026, 20:39 UTC

Charlas de Mercado

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13 feb 2026, 20:28 UTC

Charlas de Mercado

Oil Settles Week Lower -- Market Talk

13 feb 2026, 19:51 UTC

Ganancias

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 feb 2026, 19:32 UTC

Charlas de Mercado

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 feb 2026, 19:32 UTC

Charlas de Mercado

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 feb 2026, 19:29 UTC

Ganancias

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13 feb 2026, 18:18 UTC

Adquisiciones, fusiones, absorciones

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13 feb 2026, 17:52 UTC

Ganancias

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13 feb 2026, 17:16 UTC

Ganancias

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 feb 2026, 17:10 UTC

Adquisiciones, fusiones, absorciones

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13 feb 2026, 16:59 UTC

Ganancias

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13 feb 2026, 16:39 UTC

Adquisiciones, fusiones, absorciones

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13 feb 2026, 16:11 UTC

Ganancias

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13 feb 2026, 16:07 UTC

Charlas de Mercado

Hungarian Forint Could Rise Further -- Market Talk

13 feb 2026, 15:54 UTC

Ganancias

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13 feb 2026, 15:26 UTC

Charlas de Mercado

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13 feb 2026, 15:01 UTC

Ganancias

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13 feb 2026, 15:00 UTC

Ganancias

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13 feb 2026, 14:50 UTC

Charlas de Mercado

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13 feb 2026, 14:44 UTC

Ganancias

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13 feb 2026, 14:22 UTC

Charlas de Mercado

Ganancias

Global Energy Roundup: Market Talk

13 feb 2026, 14:21 UTC

Charlas de Mercado

Ganancias

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

13 feb 2026, 14:13 UTC

Charlas de Mercado

U.S. Natural Gas Futures Move Lower -- Market Talk

Comparación entre iguales

Cambio de precio

Fate Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

219.17% repunte

Estimación a 12 meses

Media 3.83 USD 219.17%

Máximo 7 USD

Mínimo 2 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Fate Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

Comprar

Mantener

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para Fate Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.9101 / 1.14Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentimiento

By Acuity

155 / 352 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.